Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group-Reference-Cited by-同舟云学术

Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group

Published:2021-02-04 Issue: Volume: Page:
ISSN:1941-6628
Container-title:Journal of Gastrointestinal Cancer
language:en
Short-container-title:J Gastrointest Canc

Author:

Gürbüz Mustafa^ORCID,Akkuş Erman^ORCID,Sakin Abdullah^ORCID,Urvay Semiha^ORCID,Demiray Atike Gökçen^ORCID,Şahin Süleyman^ORCID,Şakalar Teoman^ORCID,Erol Cihan^ORCID,Şendur Mehmet Ali Nahit^ORCID,Şahin Ahmet Bilgehan^ORCID,Çubukçu Erdem^ORCID,Güven Deniz Can^ORCID,Kılıçkap Saadettin^ORCID,Ergün Yakup^ORCID,Uncu Doğan^ORCID,Turhal Nazım Serdar^ORCID,Üskent Necdet^ORCID,Çınkır Havva Yeşil^ORCID,Demir Atakan^ORCID,Acar Ramazan^ORCID,Karadurmuş Nuri^ORCID,Türker Sema^ORCID,Altınbaş Mustafa^ORCID,Karaoğlan Mert^ORCID,Şenler Filiz Çay^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s12029-021-00594-1.pdf

Reference15 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.

2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/s0140-6736(10)61121-x.

3. Koopman T, Smits MM, Louwen M, Hage M, Boot H, Imholz AL. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J Cancer Res Clin Oncol. 2015;141(8):1343–51. https://doi.org/10.1007/s00432-014-1900-3.

4. Fornaro L, Vivaldi C, Parnofiello A, Ugolini C, Aprile G, De Maglio G, et al. Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. Br J Cancer. 2019;120(5):522–6. https://doi.org/10.1038/s41416-019-0399-4.

5. Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, et al. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer. 2008;8:363. https://doi.org/10.1186/1471-2407-8-363.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gastrointestinal Cancer Therapy and Cardiotoxicity;Current Treatment Options in Oncology;2024-08-05

2. Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study;Gastric Cancer;2023-03-07

3. Esirlikten Aristokrasiye Şigi Kutuku Noyan’ın Hayatı ve Faaliyetleri;Tarih İncelemeleri Dergisi;2022-12-30

4. Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer;Journal of the College of Physicians and Surgeons Pakistan;2022-08-01

5. Trastuzumab;Reactions Weekly;2022-07